Brief: Eliem Announces Updated Development Plans And The Advancement Of Etx-155 For The Treatment Of Major Depressive Disorder

Climb Bio

18/07/2022 12:10

July 18 (Reuters) - Eliem Therapeutics Inc  ELYM.O :
    * ELIEM ANNOUNCES UPDATED DEVELOPMENT PLANS AND THE
ADVANCEMENT OF
ETX-155 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
    * ELIEM THERAPEUTICS INC - INITIATING A PHASE 1
PHARMACOKINETICS
TRIAL OF ETX-155 TO ENABLE A PHASE 2A TRIAL IN MDD PLANNED TO
COMMENCE IN Q1 OF 2023
    * ELIEM THERAPEUTICS INC - SUFFICIENT CAPITAL EXPECTED TO
FUND
OPERATIONS UNTIL MID-2024
    * ELIEM THERAPEUTICS - ASSUMING PHASE 2A MDD TRIAL
INITIATION IN
Q1 OF 2023, TOPLINE DATA FROM TRIAL WOULD BE EXPECTED IN
MID-2024
    * ELIEM THERAPEUTICS - POSTPONING INITIATION OF PLANNED
PHASE 2A
TRIAL IN PMD, WHICH WILL PROVIDE INVESTMENT FLEXIBILITY FOR
PROGRESSION OF PIPELINE
    * ELIEM THERAPEUTICS - WILL CONSIDER RESUMING PSE TRIAL
AFTER
EXPECTED READOUT OF PHASE 1 PHARMACOKINETIC TRIAL IN Q4 OF 2022

Source text for Eikon:  ID:nGNX5sVxpn 
Further company coverage:  ELYM.O 

 ((Reuters.Briefs@thomsonreuters.com;))